About Ono

Our Products

OPDIVO® KYPROLIS® BRAFTOVI® MEKTOVI® DEMSER®
EMEND®
PROEMEND®
GLACTIV® FORXIGA® PARSABIV® RECALBON®
ORENCIA® RIVASTACH® ONOACT® STAYBLA® OPALMON®
ONON® ONON® DS

OPDIVO®

Intravenous Infusion for the Treatment of Malignant Tumors

OPDIVO® is an anticancer drug approved in Japan for cancer immunotherapy targeting PD-1, a world first. It is an immune checkpoint inhibitor that reactivates antitumor immune response using the body’s own immune system. In Japan, since its launch to the market in September 2014, OPDIVO® has been approved for 7 types of cancer (as of June 2019).

FY2018 Sales: 90.6 billion yen (Launched in September 2014)

KYPROLIS®

for Intravenous Injection for the Treatment of Malignant Tumors

KYPROLIS® is a highly selective anti-multiple myeloma drug that inhibits the action of proteasome, an enzyme complex within human cells, thereby causing functional cell death of myeloma cells.

FY2018 Sales: 4.9 billion yen (Launched in August 2016)

BRAFTOVI® Capsule

for the Treatment of Malignant Tumors

BRAFTOVI® is a BRAF inhibitor indicated for the treatment of unresectable melanoma with a BRAF mutation, in combination with MEKTOVI®, a MEK inhibitor. It suppresses the proliferation of tumors by targeting and selectively inhibiting the key enzyme of BRAF that is a family of serine/threonine kinases in the MAPK signaling pathway (RAS-RAF-MEK-ERK) associated with melanoma and various cancers. The combination therapy with MEKTOVI® is expected to provide more potent anti-tumor effects by inhibiting BRAF kinase activity and MEK1/MEK2 activity simultaneously.

(Launched in February 2019)

MEKTOVI® Tablet

for the Treatment of Malignant Tumors

MEKTOVI® is a MEK inhibitor indicated for the treatment of unresectable melanoma with a BRAF mutation, in combination with BRAFTOVI®, a BRAF inhibitor. It suppresses the proliferation of tumors by targeting and selectively inhibiting the key enzymes of MEK1/MEK2 that is a family of serine/threonine kinases in the MAPK signaling pathway (RAS-RAF-MEK-ERK) associated with melanoma and various cancers. The combination therapy with BRAFTOVI® is expected to provide more potent anti-tumor effects by inhibiting BRAF kinase activity and MEK1/MEK2 activity simultaneously.

(Launched in February 2019)

DEMSER® Capsule

for the Improvement of Status of Catecholamine Excess Secretion in Pheochromocytoma

DEMSER® is a promising drug with an efficacy in the improvement of the symptoms in patients with pheochromocytoma (PC), a neuroendocrine tumor, who are not able to sufficiently control the symptoms caused by catecholamine excessively secreted from PC—including hypertension, tachycardia, headache, palpitation—with sympatholytic drugs which have been usually used.

(Launched in February 2019)

EMEND® Capsules / PROEMEND®

for Intravenous Injection for the Treatment of Chemotherapy-induced Nausea and Vomiting

EMEND® / PROEMEND® is the first selective neurokinin (NK) 1 receptor antagonist in the world. It is effective for chemotherapy-induced nausea and vomiting. More patients with cancer are treated with immunotherapy drugs and a smaller number of patients are using an anticancer drug with high emetogenic risk.

FY2018 Sales: 10.6 billion yen (Launched in December 2009)

GLACTIV® Tablets

for the Treatment of Type 2 Diabetes

GLACTIV®, a dipeptidyl-peptidase (DPP) 4 inhibitor, is an oral drug for treatment of type 2 diabetes. It regulates blood sugar levels in type 2 diabetes patients with the mechanism of action selectively inhibiting DPP-4, an enzyme that metabolizes a gastrointestinal hormone, incretin. It thereby enhances the body’s own insulin secretion ability in a glucose dependent manner and decreases glucagon release, signaling the liver to reduce its production of glucose.

FY2018 Sales: 26.9 billion yen (Launched in December 2009)

FORXIGA® Tablets

for the Treatment of Diabetes

FORXIGA® is an oral drug for the treatment of diabetes. This drug reduces blood sugar by excreting excess blood glucose via urine through the inhibition of SGLT2, a transporter that acts to regulate reabsorption of glucose in the kidney tubules. With evidence accumulated for suppressing cardiovascular events, SGLT2 inhibitor is earning growing reputation. In March 2019, FORXIGA® was approved for additional indication of type 1 diabetes.

FY2018 Sales: 14.5 billion yen (Launched in May 2014)

PARSABIV®

Intravenous Infusion for Dialysis for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis

PARSABIV® is a drug to treat secondary hyperparathyroidism, a complication of chronic renal failure. The drug reduces the excessive secretion of the parathyroid hormone by activating the calcium-sensing receptor in the parathyroid glands and lowers the phosphorus and serum calcium levels in the blood. With the market becoming more competitive due to the entrance of competing products, PARSABIV® has been adopted by more than 80% of all the dialysis facilities in the country and its use is gradually expanding.

FY2018 Sales: 5.7 billion yen (Launched in February 2017)

RECALBON® Tablets

for the Treatment of Osteoporosis

RECALBON®, the first oral bisphosphonate (BP) discovered in Japan for the treatment of osteoporosis, is a powerful bone resorption inhibitor. It has been verified against placebo of fracture prevention effectiveness in Japanese osteoporosis patients. With the entire BP market shrinking due to strategies to promote generics use, RECALBON® is also affected by the generic products launched in June 2018.

FY2018 Sales: 7.3 billion yen (Launched in April 2009)

ORENCIA®

for Subcutaneous Injection for the Treatment of Rheumatoid Arthritis

ORENCIA® is a subcutaneous injection for the treatment of rheumatoid arthritis. It inhibits secretion of cytokines by blocking the signal that activates T cells, resulting in the suppression of joint inflammation.

FY2018 Sales: 17.4 billion yen (Launched in August 2013)

RIVASTACH® Patch

for the Treatment of Alzheimer’s Disease

RIVASTACH® Patch is a transdermal patch for the treatment of Alzheimer's disease. It reduces the progression of deteriorating cognitive functions such as memory loss (forgetfulness) and disorientation (inability to recognizing time and place) by inhibiting acetylcholinesterase and thereby increasing the amount of acetylcholine in the brain and enhancing neurotransmission.

FY2018 Sales: 8.9 billion yen (Launched in July 2011)

ONOACT®

for Intravenous Infusion for the Treatment of Tachyarrhythmia

ONOACT® is a short-acting β1 blocker that selectively blocks β1 receptors mainly found in the heart. It is for emergency treatment of intra-operative or post-operative tachyarrhythmia (atrial fibrillation, atrial flutter, sinus tachycardia), and for treatment of tachyarrhythmia in left ventricular dysfunction (atrial fibrillation, atrial flutter).

FY2018 Sales: 4.6 billion yen (Launched in September 2002)

STAYBLA® Tablets

for the Treatment of Overactive Bladder (OAB)

STAYBLA® is a selective anticholinergic antagonist binding to muscarinic acetylcholine M3 and M1 receptors. It comes in two types, regular and orodispersible (OD) tablets. It improves urge to urinate, frequent urination, and urge incontinence, the symptoms of overactive bladder, by suppressing excessive contraction of smooth muscle in the bladder.

FY2018 Sales: 3.7 billion yen (Launched in June 2007)

OPALMON® Tablets

for the Treatment of Peripheral Circulatory Disorder

OPALMON® is an orally administered prostaglandin-E1 derivative for the treatment of ischemic symptoms accompanying thromboangiitis obliterans and subjective symptoms and walking disability associated with acquired lumbar spinal canal stenosis. It improves symptoms caused by peripheral circulatory disorder such as numbness, pain or coldness of the hands or feet.

FY2018 Sales: 10.4 billion yen (Launched in July 2005)

ONON® Capsules

for the Treatment of Bronchial Asthma and Allergic Rhinitis

ONON® Capsules is a leukotriene receptor antagonist. Leukotriene is closely involved in the basic pathologies of bronchial asthma and of allergic rhinitis. The drug relieves asthma symptoms including coughing and breathlessness, and allergic rhinitis symptoms including sneezing, runny nose, and stuffy nose.

FY2018 Sales: 4.4 billion yen (Launched in January 2006)

ONON® Dry Syrup

for the Treatment of Bronchial Asthma and Allergic Rhinitis

ONON® Dry Syrup is a leukotriene receptor antagonist. Leukotriene is closely involved in the basic pathologies of bronchial asthma and of allergic rhinitis. The drug relieves asthma symptoms including coughing and breathlessness, and allergic rhinitis symptoms including sneezing, runny nose, and stuffy nose. ONON® Dry Syrup is a formulation suitable for use with pediatric patients.

FY2018 Sales: 2.7 billion yen (Launched in January 2006)